vegfr 2 dna vaccine vxm01

Drug Overview

The vegfr 2 dna vaccine vxm01, commonly known as VXM01, is a groundbreaking type of Immunotherapy and a highly specialized Targeted Therapy. Unlike traditional medicines that attack the cancer directly, this is a “Smart Drug” designed to train your own immune system to destroy the life support system of the tumor. It is a completely new approach to fighting cancer using an oral vaccine.

• Generic Name: VEGFR-2 DNA vaccine; VXM01.
• US Brand Names: None (Currently an investigational drug).
• Drug Class: Oral T-cell Immunotherapy; DNA Cancer Vaccine; Anti-angiogenic Agent.
• Route of Administration: Oral (Liquid solution taken by mouth).
• FDA Approval Status: Investigational. It is currently being studied in Phase 1 and Phase 2 clinical trials and is not yet approved by the FDA for general use.

What Is It and How Does It Work? (Mechanism of Action)

VXM01 works by cutting off the tumor’s food and oxygen supply, a process known as stopping “angiogenesis” (the creation of new blood vessels).

The Delivery System (The Weakened Bacteria)

VXM01 uses a very clever delivery method. It is made from a live, weakened strain of Salmonella bacteria (the same type of weakened bacteria used in the typhoid vaccine). This bacteria has been modified so it cannot cause disease. Instead, it acts like a Trojan horse carrying a special DNA message into your body.

Entering the Immune System

When a patient drinks the vaccine, the bacteria travel to the intestines. Here, they enter special immune checkpoints in the gut wall called Peyer’s patches. The bacteria are then swallowed by the body’s “scout cells” (macrophages and dendritic cells).

Training the Immune Army

Inside the scout cells, the DNA from the vaccine is “read” and used to create a protein called VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2).

• The Target: VEGFR-2 is a receptor heavily over-expressed on the cells that make up a tumor’s blood vessels.
• The Attack: The scout cells display this VEGFR-2 protein to the immune system’s T-cells (specifically CD8+ Killer T-cells). This trains an army of T-cells to see VEGFR-2 as a dangerous invader.

Starving the Tumor

These newly trained Killer T-cells travel through the bloodstream, hunting for VEGFR-2. When they find the blood vessels feeding the tumor, the T-cells attack and destroy them. Without a blood supply, the cancer cells starve and the tumor stops growing.

FDA-Approved Clinical Indications

Because VXM01 is an investigational drug, it does not currently have standard FDA approvals. It is only available to patients taking part in controlled clinical trials.

• Oncological Uses (In Clinical Trials):
  • Glioblastoma (GBM): An aggressive type of brain cancer (often studied in combination with other immune-boosting drugs).
  • Advanced Pancreatic Cancer.
  • Advanced Colorectal Cancer.
• Non-oncological Uses:
  • None at this time.

Dosage and Administration Protocols

Because VXM01 is an oral vaccine that must survive the harsh acids of the stomach, it is usually taken with a special liquid buffer to protect the medicine.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Since the vaccine acts locally in the gut and immune system rather than being processed heavily by the liver or kidneys, severe dose adjustments for mild organ issues are not typically required. However, patients with severe liver or kidney disease are usually excluded from early trials.
• Antibiotic Use: This is a live bacterial vaccine. Taking antibiotics will kill the vaccine before it can work. Antibiotics must be stopped well before the vaccine is given.

Clinical Efficacy and Research Results

Recent clinical trial data from 2020 to 2025 has shown exciting progress, particularly when VXM01 is paired with other drugs that take the “brakes” off the immune system.

• Glioblastoma (2025 Results): In a recent Phase 2a trial for patients with recurrent glioblastoma, VXM01 was combined with the immunotherapy drug avelumab. The combination was well tolerated. In patients whose tumors could not be removed by surgery, the therapy achieved an Objective Response Rate (ORR) of 12%.
• Survival Rates: For these glioblastoma patients, the median Overall Survival (OS) was 11.1 months, with a 12-month survival rate of 52%. This is a very encouraging result for a disease that is notoriously difficult to treat.
• Pancreatic Cancer: Studies have shown that VXM01 successfully triggers a strong, measurable increase in VEGFR-2 specific T-cells in the blood. While it may not cure the disease alone, it modifies the tumor’s environment, potentially making other therapies work better.

Safety Profile and Side Effects

VXM01 has been shown to be safe and generally well-tolerated in clinical trials, but because it involves a live bacteria and triggers an immune response, it comes with specific side effects.

Safety Note: There is no official “Black Box Warning” for VXM01 yet. However, because it is a live-attenuated vaccine, it carries risks for patients with severely weakened immune systems (such as those with HIV or taking heavy immune-suppressing drugs).

Common Side Effects (>10%)

• Diarrhea and Upset Stomach: The most common side effect, as the bacterial vector works in the intestines.
• Mild Fever and Chills: A normal sign that the immune system is activating.
• Lymphopenia: A temporary drop in the number of certain white blood cells in the blood.
• Fatigue: Feeling unusually tired.

Serious Adverse Events

• Severe Gastrointestinal Issues: Heavy, prolonged diarrhea that could lead to dehydration.
• Overactive Immune Response: Because it attacks blood vessels, there is a theoretical risk of impaired wound healing or bleeding, though severe instances have been rare in trials.

Management Strategies

• Hydration: Patients experiencing diarrhea must drink plenty of fluids containing electrolytes to prevent dehydration.
• Fever Reducers: Mild fevers can usually be managed with standard over-the-counter medicines like acetaminophen, as directed by the doctor.

Connection to Stem Cell and Regenerative Medicine

VXM01 is a major topic in the study of the Tumor Microenvironment (TME). Tumors build a tough, chaotic shield of blood vessels and cells around themselves that prevents normal immune cells and chemotherapy from getting inside. By destroying these abnormal blood vessels, VXM01 helps to “remodel” or break down this shield. Researchers are studying how this vaccine can be used to clear the path for advanced Cellular Therapies (like CAR-T cells or engineered stem cells), allowing these powerful treatments to penetrate deeply into solid tumors where they were previously blocked.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Immune System Check: Complete blood counts to ensure you have enough healthy immune cells for the vaccine to “train.”
• Pregnancy Test: Mandatory for women of childbearing age, as the effect of the vaccine on a growing fetus is unknown.

Precautions During Treatment

• Hand Hygiene: Because you are swallowing a live (though weakened) bacteria, you must wash your hands very thoroughly with soap and water after using the restroom to prevent spreading the bacteria to others.
• Dietary Rules: You will be asked to take the vaccine on an empty stomach (fasting for a few hours before and after) so food does not interfere with the medicine.

“Do’s and Don’ts” list

• DO tell your doctor immediately if you develop a high fever or severe, watery diarrhea.
• DO inform all your healthcare providers that you are taking a live bacterial vaccine.
• DON’T take any antibiotics without talking to your oncologist first, as they will destroy the vaccine.
• DON’T take stomach acid reducers (like Tums or omeprazole) right before your dose unless your doctor specifically tells you to, as stomach acid levels affect how the vaccine is absorbed.

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. VEGFR-2 DNA vaccine VXM01 is an investigational medication and is only available to patients participating in approved clinical trials. Always consult your oncologist or licensed healthcare provider regarding your specific medical condition and treatment options. Individual results and side effects from clinical trials may vary.